Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Price was the key driver for the period
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Laxxon Medical has developed a 3D screen printing technology for the manufacture of structured tablets that enables the controlled release of active pharmaceutical ingredients over time
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Subscribe To Our Newsletter & Stay Updated
